← Back to Search

Retinoid

S6G5T-3 for Acne

Phase 1
Waitlist Available
Research Sponsored by Sol-Gel Technologies, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

Study Summary

To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetics of S6G5T-3 as measured by the maximum observed plasma concentration

Side effects data

From 2019 Phase 3 trial • 434 Patients • NCT03761810
10%
Application site pain
4%
Application site dryness
3%
Application site erythema
3%
Application site exfoliation
2%
Application site dermatitis
2%
Application site pruritus
1%
Application site photosensitivity
1%
Nasopharyngitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
S6G5T-3
S6G5T-8 Vehicle Cream

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: S6G5T-3Experimental Treatment1 Intervention
topical cream
Group II: Retin-A® 0.1% CreamActive Control1 Intervention
topical cream
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
S6G5T-3
2018
Completed Phase 3
~1650

Find a Location

Who is running the clinical trial?

Sol-Gel Technologies, Ltd.Lead Sponsor
13 Previous Clinical Trials
4,026 Total Patients Enrolled
~10 spots leftby Jun 2025